Unibest

Pharmaceutical intermediates

Rotigotine Intermediates

5 pharmaceutical intermediates for Rotigotine. Indication: Restless legs syndrome; Parkinson's disease.

提交项目All intermediates

About Rotigotine

Originator
Ucb Inc.
Indication
Restless legs syndrome; Parkinson's disease
Approved Date
04/02/2012
DS/DP
11/27/2025

Available intermediates

5 intermediates currently listed for Rotigotine. Request specifications, documentation or a quotation for any item below.

Rotigotine intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
5-Methoxy-2-tetralone32940-15-1//
(S)-2-AMINO-5-METHOXYTETRALIN HYDROCHLORIDE105086-80-4//
(S)-2-Amino-5-methoxytetralin Hydrochloride58349-17-0//
(S)-1,2,3,4-Tetrahydro-5-methoxy-N-propyl-2-naphthalenamine hydrochloride93601-86-6//
(S)-2-Amino-5-methoxytetralin (S)-mandelate439133-67-2//

Other programs under R

Ramelteon RegorafenibRelugolixRemdesivir RemibrutinibRepotrectinibResmetiromRevumenib

Building toward Rotigotine?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →